Skystar Bio-Pharmaceutical Co (FRA:GNJC) Capex-to-Operating-Cash-Flow : 0.14 (As of Sep. 2014)

Skystar Bio-Pharmaceutical Co Capex-to-Operating-Cash-Flow Chart

Skystar Bio-Pharmaceutical Co Annual Data
	Trend	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Dec13
Capex-to-Operating-Cash-Flow		Get a 7-Day Free Trial					3.49	0.54	-	0.09	-

Skystar Bio-Pharmaceutical Co Quarterly Data
	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14
Capex-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	0.01	0.01	0.14

Competitive Comparison of Skystar Bio-Pharmaceutical Co's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - General subindustry, Skystar Bio-Pharmaceutical Co's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Skystar Bio-Pharmaceutical Co's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Skystar Bio-Pharmaceutical Co's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Skystar Bio-Pharmaceutical Co's Capex-to-Operating-Cash-Flow falls into.

Skystar Bio-Pharmaceutical Co Capex-to-Operating-Cash-Flow Calculation

Skystar Bio-Pharmaceutical Co's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2013 is calculated as

Skystar Bio-Pharmaceutical Co's Capex-to-Operating-Cash-Flow for the quarter that ended in Sep. 2014 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Skystar Bio-Pharmaceutical Co  (FRA:GNJC) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.

Skystar Bio-Pharmaceutical Co Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Skystar Bio-Pharmaceutical Co's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Skystar Bio-Pharmaceutical Co Business Description